Search - tctmd.com

Displaying 241 - 260 of 331

Sort: Relevancy | Date

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

Mystery Case 2

Presenter: Jennifer Ho

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Mauro Moscucci

March 20, 2023

Presentation THT 2023

How Do We Improve Advanced Heart Failure Outcomes in ACHD? ACTION Learning Network

Presenter: Ari Cedars

March 20, 2023

Presentation THT 2023

Mystery Case 1

Presenter: Hannah R. Rosenblum

March 20, 2023

Presentation THT 2023

What's the Status of Advanced Heart Failure Care in ACHD Now? MCS, Listing Status and Outcomes

Presenter: Jonathan Menachem

March 20, 2023

Presentation THT 2023

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Presenter: Maria Rosa Costanzo

March 20, 2023

Presentation THT 2023

Interventional Therapies for HFpEF

Presenter: Sanjiv Shah

March 20, 2023

Presentation THT 2023

Medical Therapies Work for HFpEF: What, When, How

Presenter: Parag Goyal

March 20, 2023

Presentation THT 2023

Medical Therapy for Advanced Heart Failure in ACHD: What's On the Horizon?

Presenter: Christopher Broda

March 20, 2023

Presentation THT 2023

New Insights Into the Pathophysiology of HFpEF

Presenter: Philipp Lurz

March 20, 2023

Presentation THT 2023

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

Presenter: Ulrich Jorde

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Meir Shinnar

March 20, 2023

Presentation THT 2023

The Multiverse of HFpEF: All Roads Lead to Functional Limitation

Presenter: Greg Lewis

March 20, 2023

Presentation THT 2023

Advanced Heart Failure in ACHD - How Do We Define It?

Presenter: Christopher Learn

March 20, 2023

Presentation THT 2023

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Presenter: Song Li

March 20, 2023

Presentation THT 2023

Applications of Gene Therapy in Cardiomyopathies (TBD)

Presenter: Eric Adler

March 20, 2023

Presentation THT 2023

Biomarkers and Risk Stratification for Cardiogenic Shock

Presenter: Ajar Kochar

March 20, 2023

Presentation THT 2023

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Presenter: David Baran

March 20, 2023

Advertisement

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Mystery Case 2

FDA Introduction

How Do We Improve Advanced Heart Failure Outcomes in ACHD? ACTION Learning Network

Mystery Case 1

What's the Status of Advanced Heart Failure Care in ACHD Now? MCS, Listing Status and Outcomes

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Interventional Therapies for HFpEF

Medical Therapies Work for HFpEF: What, When, How

Medical Therapy for Advanced Heart Failure in ACHD: What's On the Horizon?

New Insights Into the Pathophysiology of HFpEF

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

FDA Introduction

The Multiverse of HFpEF: All Roads Lead to Functional Limitation

Advanced Heart Failure in ACHD - How Do We Define It?

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

Applications of Gene Therapy in Cardiomyopathies (TBD)

Biomarkers and Risk Stratification for Cardiogenic Shock

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content